866-997-4948(US-Canada Toll Free)

Muscular Dystrophy - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Nov 2010

Category :

Therapeutic Area

No. of Pages : 41 Pages


GlobalData, the industry analysis specialist, has released its new report, Muscular Dystrophy Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global muscular dystrophy therapeutics market and pipeline The report identifies the key trends shaping and driving the global muscular dystrophy therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global muscular dystrophy therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts. GlobalData has estimated the global muscular dystrophy therapeutics market to be valued at $115 m in 2009. It is expected to increase to $156 m with a Compound Annual Growth Rate (CAGR) of (3.9%) by 2017. There is a high unmet need in the current muscular dystrophy therapeutics market in terms of both safety and efficacy profile. New high potential drugs muscular dystrophy therapeutics are expected to come in the market after 2017.

Scope

The report provides information on the key drivers and challenges of the muscular dystrophy therapeutics market. Its scope includes -

  • Annualized global muscular dystrophy therapeutics market revenues data from 2001 to 2009, forecast for eight years to 2017.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major classes such as exon inhibitor and antioxidants.
  • Analysis of the current and future competition in the global muscular dystrophy therapeutics market. Key market players covered are PTC therapeutics, Genzyme corporation, Santhera pharmaceuticals, Takeda Biopharmaceuticals, Avi Biopharma, Insmed Incorporated, GlaxoSmithKline, Prosena Therapeutics B.V.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the muscular dystrophy therapeutics market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global muscular dystrophy therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global muscular dystrophy therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • Whats the next big thing in the global muscular dystrophy therapeutics market landscape? Identify, understand and capitalize.
Table Of Content

1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Muscular Dystrophy Therapeutics - Introduction 5
2.1 Overview 5
2.2 GlobalData Pipeline Report Guide 6

3 Muscular Dystrophy Therapeutics - Market Characterization 7
3.1 Muscular Dystrophy Therapeutics Market Size 7
3.2 Muscular Dystrophy Therapeutics Market Forecast and CAGR 8
3.3 Drivers and Barriers for the Muscular Dystrophy Therapeutics Market 9
3.3.1 Drivers for the Muscular Dystrophy Therapeutics Market 9
3.3.2 Barriers for the Muscular Dystrophy Therapeutics Market 10
3.3.3 Prescription Rate 10
3.4 Opportunity and Unmet Need 11
3.5 Key Takeaway 12

4 Global Muscular Muscular Dystrophy Therapeutics Market - Competitive Assessment 13
4.1 Overview 13
4.2 Strategic Competitor Assessment 13
4.3 Product Profile for the Major Marketed Products in the Muscular Dystrophy Therapeutics Market 14
4.3.1 Cosrticosteriods 14
4.3.2 Prednisone 14
4.3.3 Deflazacort 15
4.4 Key Takeaway 15

5 Global Muscular Dystrophy Therapeutics Market - Pipeline Assessment 16
5.1 Overview 16
5.2 Strategic Pipeline Assessment 16
5.3 Muscular Dystrophy Therapeutics Market Promising Drugs Under Clinical Development 18
5.4 Molecule Profile for Promising Drugs under Clinical Development 19
5.4.1 Catena/Sovrima (Idebenone) 19
5.4.2 Ataluren (PTC124) 19
5.4.3 IPlex (Mecasermin Rinfabate) 20
5.4.4 GSK 2402968 / PRO051 20
5.5 Muscular Dystrophy Therapeutics Market Clinical Pipeline by Mechanism of Action 21
5.5.1 Muscular Dystrophy Phase III Clinical Pipeline 22
5.5.2 Muscular Dystrophy Phase II Clinical Pipeline 23
5.5.3 Muscular Dystrophy Phase I Clinical Pipeline 23
5.5.4 Muscular Dystrophy Pre-clinical Pipeline 24
5.6 Key Takeaway 24

6 Global Muscular Dystrophy Therapeutics Market - Implications for Future Market Competition 25

7 Global Muscular Dystrophy Therapeutics Market - Future Players 26
7.1 Introduction 26
7.2 PTC Therapeutics, Inc 26
7.2.1 Company Overview 26
7.2.2 Business Description 27
7.3 Genzyme Corporation 27
7.3.1 Company Overview 27
7.3.2 Business Description 27
7.4 Santhera Pharmaceuticals AG 28
7.4.1 Company Overview 28
7.4.2 Business Description 28
7.5 Takeda Pharmaceuticals 30
7.5.1 Overview 30
7.5.2 Business Description 30
7.6 Avi Biopharma 30
7.6.1 Company Overview 30
7.6.2 Business Description 30
7.7 Insmed Incorporated 31
7.7.1 Company Overview 31
7.7.2 Business Description 32
7.8 GlaxoSmithKline 33
7.8.1 Company Overview 33
7.8.2 Business Description 33
7.9 Prosensa Therapeutics B.V. 34

8 Muscular Dystrophy Therapeutics Market: Appendix 35
8.1 Definitions 35
8.2 Acronyms 35
8.3 Research Methodology 35
8.3.1 Coverage 36
8.3.2 Secondary Research 36
8.3.3 Forecasting 36
8.3.4 Primary Research 39
8.3.5 Expert Panels 39
8.4 Contact Us 39
8.5 Disclaimer 39
8.6 Sources 40

List of Table


Table 1: Muscular Dystrophy Therapeutics Market, Global, Revenue ($m), 20012009 7
Table 2: Muscular Dystrophy Therapeutics Market, Global, Market Forecast ($m), 20092017 8
Table 3: Muscular Dystrophy, Major Marketed Products Comparison, 2010 15
Table 4: Muscular Dystrophy Syndrome Most Promising Drugs Under Clinical Development, 2010 18
Table 5: Muscular Dystrophy Therapeutics Phase III Clinical Pipeline, 2010 23
Table 6: Muscular Dystrophy Therapeutics Phase II Clinical Pipeline, 2010 24
Table 7: Muscular Dystrophy Therapeutics Phase I Clinical Pipeline, 2010 24
Table 8: Muscular Dystrophy Therapeutics Pre-clinical and Discovery Pipeline, 2010 25
Table 11: PTC Therapeutics Muscular Dystrophy Pipeline Product Portfolio, 2010 28
Table 12: Genzyme Corporation Muscular Dystrophy Pipeline Product Portfolio, 2010 29
Table 13: Santhera Pharmaceuticals - Muscular Dystrophy Pipeline Product Portfolio, 2010 30
Table 14: Takeda Pharmaceuticals - Muscular Dystrophy Pipeline Product Portfolio, 2010 31
Table 15: Avi Biopharma - Muscular Dystrophy Pipeline Product Portfolio, 2010 32
Table 16: Insmed Incorporated - Muscular Dystrophy Pipeline Product Portfolio, 2010 33
Table 17: GlaxoSmithKline - Muscular Dystrophy Pipeline Product Portfolio, 2010 34
Table 18: Prosena Therapeutics B.V. - Muscular Dystrophy Pipeline Product Portfolio, 2010 35

List of Chart


Figure 1: Muscular Dystrophy Therapeutics Market, Global, Revenue ($m), 2001-2009 7
Figure 2: Muscular Dystrophy Therapeutics Market, Global, Market Forecast ($m), 2009-2017 8
Figure 3: Opportunity and Unmet Need in the Muscular Dystrophy Therapeutic Market, 2010 11
Figure 4: Strategic Competitor Assessment of the Muscular Dystrophy Therapeutic Market, 2010 13
Figure 5: Technology Trends Analytics, Framework of the Muscular Dystrophy Pipeline, 2010 17
Figure 6: Technology Trends Analytics, Framework of the Muscular Dystrophy Pipeline Description, 2010 18
Figure 7: Muscular Dystrophy Therapeutics Market Clinical Pipeline by Mechanism of Action, 2010 22
Figure 8: Muscular Dystrophy Therapeutics Market Clinical Pipeline by Phase of Development, 2010 23
Figure 10: Implications for Future Market Competition in the Muscular Dystrophy Therapeutics Market, 2010 26
Figure 12: GlobalData Market Forecasting Model 39

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *